N-11 truncated amyloid-beta A 11-x monoclonal antibodies and compositions

This invention relates to antibodies, including specified portions or variants, specific for at least the human Amyloid-beta 11 N-terminal site, i.e. A 11-x peptides. It further provides methods of making and using said antibodies, including therapeutic formulations, administration and devices.

Saved in:
Bibliographic Details
Main Authors MERCKEN MARC HUBERT, VANDERMEEREN MARC MARIA PIERRE
Format Patent
LanguageEnglish
Published 03.05.2016
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE
HUMAN NECESSITIES
HYGIENE
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES
MEASURING
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
ORGANIC CHEMISTRY
PEPTIDES
PHYSICS
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPIRITS
TESTING
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:This invention relates to antibodies, including specified portions or variants, specific for at least the human Amyloid-beta 11 N-terminal site, i.e. A 11-x peptides. It further provides methods of making and using said antibodies, including therapeutic formulations, administration and devices.
Bibliography:Application Number: US20030528928